Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 886 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Traws Pharma Inc | TRAW | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0265 | -4.03% | 0.6309 | 09:12:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.6574 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 14 | 886 | - | 0.601 - 0.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:03:24 | 40 | $ 0.6624 | USD |
Traws Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 21M | 21.00M | - | 226k | -18.95M | -0.90 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Traws Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRAW Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.66 | 0.67 | 0.61 | 0.6494535 | 39,664 | -0.0291 | -4.41% |
| 1 Month | 0.71 | 0.72 | 0.601 | 0.6500202 | 44,372 | -0.0791 | -11.14% |
| 3 Months | 0.99 | 0.99 | 0.601 | 0.7757316 | 110,388 | -0.3591 | -36.27% |
| 6 Months | 0.99 | 0.99 | 0.601 | 0.7757316 | 110,388 | -0.3591 | -36.27% |
| 1 Year | 0.99 | 0.99 | 0.601 | 0.7757316 | 110,388 | -0.3591 | -36.27% |
| 3 Years | 0.99 | 0.99 | 0.601 | 0.7757316 | 110,388 | -0.3591 | -36.27% |
| 5 Years | 0.99 | 0.99 | 0.601 | 0.7757316 | 110,388 | -0.3591 | -36.27% |
Traws Pharma Description
| Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. |
